

REFERENCES

- Adida, C., Berrebi, D., Peuchmaur, M., Reyes-Mugica, M., & Altieri, D. C. (1998). Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. *Lancet*, *351*(9106), 882-883.
- Adida, C., Crotty, P. L., McGrath, J., Berrebi, D., Diebold, J., & Altieri, D. C. (1998). Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. *Am J Pathol*, *152*(1), 43-49.
- Adida, C., Recher, C., Raffoux, E., Daniel, M. T., Taksin, A. L., Rousselot, P., et al. (2000). Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. *Br J Haematol*, *111*(1), 196-203.
- Altieri, D. C. (2001). The molecular basis and potential role of survivin in cancer diagnosis and therapy. *Trends Mol Med*, *7*(12), 542-547.
- Altieri, D. C. (2003). Survivin, versatile modulation of cell division and apoptosis in cancer. *Oncogene*, *22*(53), 8581-8589.
- Altieri, D. C. (2003). Validating survivin as a cancer therapeutic target. *Nat Rev Cancer*, *3*(1), 46-54.
- Ambion, I. (2006). Denaturing Agarose Gel Electrophoresis of RNA [Online]. Available: http://www.ambion.com/techlib/append/supp/rna_gel.html [2006, October 28].

- Ambrosini, G., Adida, C., & Altieri, D. C. (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. *Nat Med*, 3(8), 917-921.
- Asanuma, K., Moriai, R., Yajima, T., Yagihashi, A., Yamada, M., Kobayashi, D., et al. (2000). Survivin as a radioresistance factor in pancreatic cancer. *Jpn J Cancer Res*, 91(11), 1204-1209.
- Badran, A., Yoshida, A., Ishikawa, K., Goi, T., Yamaguchi, A., Ueda, T., et al. (2004). Identification of a novel splice variant of the human anti-apoptosis gene survivin. *Biochem Biophys Res Commun*, 314(3), 902-907.
- Bedi, A., Pasricha, P. J., Akhtar, A. J., Barber, J. P., Bedi, G. C., Giardiello, F. M., et al. (1995). Inhibition of apoptosis during development of colorectal cancer. *Cancer Res*, 55(9), 1811-1816.
- Ben-Mahrez, K., Sorokine, I., Thierry, D., Kawasumi, T., Ishii, S., Salmon, R., et al. (1990). Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. *Int J Cancer*, 46(1), 35-38.
- Bhatia, P., Taylor, W. R., Greenberg, A. H., & Wright, J. A. (1994). Comparison of glyceraldehyde-3-phosphate dehydrogenase and 28S-ribosomal RNA gene expression as RNA loading controls for northern blot analysis of cell lines of varying malignant potential. *Anal Biochem*, 216(1), 223-226.
- Blanc-Brude, O. P., Mesri, M., Wall, N. R., Plescia, J., Dohi, T., & Altieri, D. C. (2003). Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. *Clin Cancer Res*, 9(7), 2683-2692.

- Borbely, A. A., Murvai, M., Szarka, K., Konya, J., Gergely, L., Hernadi, Z., et al. (2006). Survivin promoter polymorphism and cervical carcinogenesis. *J Clin Pathol*.
- Broders, A. C. (1926). Carcinoma:grading and practical application. *Arch Pathol*, 2, 376-381.
- Budihardjo, I., Oliver, H., Lutter, M., Luo, X., & Wang, X. (1999). Biochemical pathways of caspase activation during apoptosis. *Annu Rev Cell Dev Biol*, 15, 269-290.
- Caldas, H., Honsey, L. E., & Altura, R. A. (2005). Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. *Mol Cancer*, 4(1), 11.
- Carding, S. R., Lu, D., & Bottomly, K. (1992). A polymerase chain reaction assay for the detection and quantitation of cytokine gene expression in small numbers of cells. *J Immunol Methods*, 151(1-2), 277-287.
- Carson, J. P., Behnam, M., Sutton, J. N., Du, C., Wang, X., Hunt, D. F., et al. (2002). Smac is required for cytochrome c-induced apoptosis in prostate cancer LNCaP cells. *Cancer Res*, 62(1), 18-23.
- Carvalho, A., Carmena, M., Sambade, C., Earnshaw, W. C., & Wheatley, S. P. (2003). Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. *J Cell Sci*, 116(Pt 14), 2987-2998.
- Chang, J. T., Wong, F. H., Liao, C. T., Chen, I. H., Wang, H. M., & Cheng, A. J. (2004). Enzyme immunoassay for serum autoantibody to survivin and its findings in head-and-neck cancer patients. *Clin Chem*, 50(7), 1261-1264.

- Chantalat, L., Skoufias, D. A., Kleman, J. P., Jung, B., Dideberg, O., & Margolis, R. L. (2000). Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. *Mol Cell*, 6(1), 183-189.
- Chen, W. C., Liu, Q., Fu, J. X., & Kang, S. Y. (2004). Expression of survivin and its significance in colorectal cancer. *World J Gastroenterol*, 10(19), 2886-2889.
- Chiou, S. K., Jones, M. K., & Tarnawski, A. S. (2003). Survivin - an anti-apoptosis protein: its biological roles and implications for cancer and beyond. *Med Sci Monit*, 9(4), PI25-29.
- Cordiano, I., Steffan, A., Randi, M. L., Pradella, P., Girolami, A., & Fabris, F. (1995). Biotin-avidin immobilization of platelet glycoproteins (BAIPG): a new capture assay for the detection of anti-platelet antibodies. *J Immunol Methods*, 178(1), 121-130.
- Crawford, L. V., Pim, D. C., & Bulbrook, R. D. (1982). Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. *Int J Cancer*, 30(4), 403-408.
- Crook, N. E., Clem, R. J., & Miller, L. K. (1993). An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. *J Virol*, 67(4), 2168-2174.
- Dale, G. L., Gaddy, P., & Pikul, F. J. (1994). Antibodies against biotinylated proteins are present in normal human serum. *J Lab Clin Med*, 123(3), 365-371.
- Deveraux, Q. L., & Reed, J. C. (1999). IAP family proteins--suppressors of apoptosis. *Genes Dev*, 13(3), 239-252.
- Dukes, C. E. (1932). The classification of cancer of the rectum. *J Pathol Bacteriol*, 35, 323-332.

- Dukes, C. E. (1950). The relation of histology to spread in intestinal cancer. *Br J Cancer*, 4(1), 59-62.
- Earnshaw, W. C., Martins, L. M., & Kaufmann, S. H. (1999). Mammalian caspases: structure, activation, substrates, and functions during apoptosis. *Annu Rev Biochem*, 68, 383-424.
- Ellis, R. E., Yuan, J. Y., & Horvitz, H. R. (1991). Mechanisms and functions of cell death. *Annu Rev Cell Biol*, 7, 663-698.
- Fielding, L. P., Fenoglio-Preiser, C. M., & Freedman, L. S. (1992). The future of prognostic factors in outcome prediction for patients with cancer. *Cancer*, 70(9), 2367-2377.
- Fleming, I. D., Cooper, J. S., Henson, D. E., Hutter, R. V. P., Kennedy, B. J., Murphy, G. P., et al. (1997). *Manual for staging of cancer of the American Joint Committee on Cancer* (5 th ed.). Philadelphia: Lippincott, J.B.
- Fortugno, P., Wall, N. R., Giodini, A., O'Connor, D. S., Plescia, J., Padgett, K. M., et al. (2002). Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. *J Cell Sci*, 115(Pt 3), 575-585.
- Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000). Cancer statistics, 2000. *CA Cancer J Clin*, 50(1), 7-33.
- Hattori, M., Sakamoto, H., Satoh, K., & Yamamoto, T. (2001). DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. *Cancer Lett*, 169(2), 155-164.

- Hofstra. (2006). UV Spectrophotometric Analysis of DNA and RNA [Online]. Available: http://people.hofstra.edu/faculty/Beverly_Clendening/Adv_Molecular_Biology/Protocols/UV_Spec_Analysis_RNA&DNA.htm [2006, October 28].
- Ikeguchi, M., Ueda, T., Sakatani, T., Hirooka, Y., & Kaibara, N. (2002). Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. *Diagn Mol Pathol*, *11*(1), 33-40.
- Ikehara, M., Oshita, F., Kameda, Y., Ito, H., Ohgane, N., Suzuki, R., et al. (2002). Expression of survivin correlated with vessel invasion is a marker of poor prognosis in small adenocarcinoma of the lung. *Oncol Rep*, *9*(4), 835-838.
- Islam, A., Kageyama, H., Takada, N., Kawamoto, T., Takayasu, H., Isogai, E., et al. (2000). High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. *Oncogene*, *19*(5), 617-623.
- Ito, T., Shiraki, K., Sugimoto, K., Yamanaka, T., Fujikawa, K., Ito, M., et al. (2000). Survivin promotes cell proliferation in human hepatocellular carcinoma. *Hepatology*, *31*(5), 1080-1085.
- Jacobson, M. D., Weil, M., & Raff, M. C. (1997). Programmed cell death in animal development. *Cell*, *88*(3), 347-354.
- Jarnagin, W. R., Weber, S., Tickoo, S. K., Koea, J. B., Obiekwe, S., Fong, Y., et al. (2002). Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. *Cancer*, *94*(7), 2040-2046.

- Jia, L., Patwari, Y., Kelsey, S. M., Srinivasula, S. M., Agrawal, S. G., Alnemri, E. S., et al. (2003). Role of Smac in human leukaemic cell apoptosis and proliferation. *Oncogene*, 22(11), 1589-1599.
- Johnson, M. E., & Howerth, E. W. (2004). Survivin: a bifunctional inhibitor of apoptosis protein. *Vet Pathol*, 41(6), 599-607.
- Johnstone, R. W., Ruefli, A. A., & Lowe, S. W. (2002). Apoptosis: a link between cancer genetics and chemotherapy. *Cell*, 108(2), 153-164.
- Joza, N., Susin, S. A., Daugas, E., Stanford, W. L., Cho, S. K., Li, C. Y., et al. (2001). Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. *Nature*, 410(6828), 549-554.
- Kamihira, S., Yamada, Y., Hirakata, Y., Tomonaga, M., Sugahara, K., Hayashi, T., et al. (2001). Aberrant expression of caspase cascade regulatory genes in adult T-cell leukaemia: survivin is an important determinant for prognosis. *Br J Haematol*, 114(1), 63-69.
- Karp, G. (1999). *Cell and molecular biology: concepts and experiments* (2 nd ed.): John Wiley & Sons.
- Kato, J., Kuwabara, Y., Mitani, M., Shinoda, N., Sato, A., Toyama, T., et al. (2001). Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. *Int J Cancer*, 95(2), 92-95.
- Kaufmann, S. H., & Gores, G. J. (2000). Apoptosis in cancer: cause and cure. *Bioessays*, 22(11), 1007-1017.
- Kawasaki, H., Altieri, D. C., Lu, C. D., Toyoda, M., Tenjo, T., & Tanigawa, N. (1998). Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. *Cancer Res*, 58(22), 5071-5074.

- Kawasaki, H., Toyoda, M., Shinohara, H., Okuda, J., Watanabe, I., Yamamoto, T., et al. (2001). Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. *Cancer*, *91*(11), 2026-2032.
- Kerr, J. F., Winterford, C. M., & Harmon, B. V. (1994). Apoptosis. Its significance in cancer and cancer therapy. *Cancer*, *73*(8), 2013-2026.
- Kerr, J. F., Wyllie, A. H., & Currie, A. R. (1972). Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br J Cancer*, *26*(4), 239-257.
- Kim, M. J., Lim, K. Y., Kim, J. W., Nam, I. W., Lee, J. H., & Myoung, H. (2005). Stage and mRNA expression of survivin in lymph node as prognostic indicators in patients with oral squamous cell carcinoma. *Cancer Lett*, *224*(2), 253-261.
- Kinzler, K. W., & Vogelstein, B. (1998). Landscaping the cancer terrain. *Science*, *280*(5366), 1036-1037.
- Konno, R., Yamakawa, H., Utsunomiya, H., Ito, K., Sato, S., & Yajima, A. (2000). Expression of survivin and Bcl-2 in the normal human endometrium. *Mol Hum Reprod*, *6*(6), 529-534.
- Korn, W. M. (2001). Moving toward an understanding of the metastatic process in hepatocellular carcinoma. *World J Gastroenterol*, *7*(6), 777-778.
- Koziol, J. A., Zhang, J. Y., Casiano, C. A., Peng, X. X., Shi, F. D., Feng, A. C., et al. (2003). Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. *Clin Cancer Res*, *9*(14), 5120-5126.

- Krieg, A., Mahotka, C., Krieg, T., Grabsch, H., Muller, W., Takeno, S., et al. (2002). Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. *Br J Cancer*, 86(5), 737-743.
- Li, F. (2003). Survivin study: what is the next wave? *J Cell Physiol*, 197(1), 8-29.
- Li, F. (2005). Role of survivin and its splice variants in tumorigenesis. *Br J Cancer*, 92(2), 212-216.
- Li, F., Ackermann, E. J., Bennett, C. F., Rothermel, A. L., Plescia, J., Tognin, S., et al. (1999). Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. *Nat Cell Biol*, 1(8), 461-466.
- Li, F., Ambrosini, G., Chu, E. Y., Plescia, J., Tognin, S., Marchisio, P. C., et al. (1998). Control of apoptosis and mitotic spindle checkpoint by survivin. *Nature*, 396(6711), 580-584.
- Li, F., & Ling, X. (2006). Survivin study: an update of "what is the next wave"? *J Cell Physiol*, 208(3), 476-486.
- Lin, C. W., Manshour, T., Jilani, I., Neuber, D., Patel, K., Kantarjian, H., et al. (2002). Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome. *Leuk Res*, 26(6), 551-559.
- Lin, L. J., Zheng, C. Q., Jin, Y., Ma, Y., Jiang, W. G., & Ma, T. (2003). Expression of survivin protein in human colorectal carcinogenesis. *World J Gastroenterol*, 9(5), 974-977.
- Lu, C. D., Altieri, D. C., & Tanigawa, N. (1998). Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. *Cancer Res*, 58(9), 1808-1812.

- Mahotka, C., Wenzel, M., Springer, E., Gabbert, H. E., & Gerharz, C. D. (1999). Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. *Cancer Res*, 59(24), 6097-6102.
- Martin, N., & Patel, N. (1996). *Cancer incidence and leading sites*. [Online]. Available:http://61.90.198.162/file_download/Cancer%20In%20Thailand/CHARTER2.pdf [2006, October 28].
- Massion, P. P., & Carbone, D. P. (2003). The molecular basis of lung cancer: molecular abnormalities and therapeutic implications. *Respir Res*, 4, 12.
- McConkey, D. J., Chandra, J., Wright, S., Plunkett, W., McDonnell, T. J., Reed, J. C., et al. (1996). Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. *J Immunol*, 156(7), 2624-2630.
- Meghiorino, R., Shi, F. D., Peng, X. X., Wang, X., Chan, E. K., Tan, E. M., et al. (2005). Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. *Cancer Detect Prev*, 29(3), 241-248.
- Meier, P., Finch, A., & Evan, G. (2000). Apoptosis in development. *Nature*, 407(6805), 796-801.
- Meng, H., Lu, C., Mabuchi, H., & Tanigawa, N. (2004). Prognostic significance and different properties of survivin splicing variants in gastric cancer. *Cancer Lett*, 216(2), 147-155.

- Monzo, M., Rosell, R., Felip, E., Astudillo, J., Sanchez, J. J., Maestre, J., et al. (1999). A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. *J Clin Oncol*, 17(7), 2100-2104.
- Morinaga, S., Nakamura, Y., Ishiwa, N., Yoshikawa, T., Noguchi, Y., Yamamoto, Y., et al. (2004). Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma. *Oncol Rep*, 12(6), 1189-1194.
- Mountain, C. F. (1995). New prognostic factors in lung cancer. Biologic prophets of cancer cell aggression. *Chest*, 108(1), 246-254.
- Nachmias, B., Ashhab, Y., & Ben-Yehuda, D. (2004). The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. *Semin Cancer Biol*, 14(4), 231-243.
- Nasrin, N., Ercolani, L., Denaro, M., Kong, X. F., Kang, I., & Alexander, M. (1990). An insulin response element in the glyceraldehyde-3-phosphate dehydrogenase gene binds a nuclear protein induced by insulin in cultured cells and by nutritional manipulations in vivo. *Proc Natl Acad Sci U S A*, 87(14), 5273-5277.
- Nicholson, D. W. (1999). Caspase structure, proteolytic substrates, and function during apoptotic cell death. *Cell Death Differ*, 6(11), 1028-1042.
- Niklinski, J., & Furman, M. (1995). Clinical tumour markers in lung cancer. *Eur J Cancer Prev*, 4(2), 129-138.

- Niklinski, J., Niklinska, W., Chyczewski, L., Becker, H. D., & Pluygers, E. (2001). Molecular genetic abnormalities in premalignant lung lesions: biological and clinical implications. *Eur J Cancer Prev*, *10*(3), 213-226.
- Niklinski, J., Niklinska, W., Laudanski, J., Chyczewska, E., & Chyczewski, L. (2001). Prognostic molecular markers in non-small cell lung cancer. *Lung Cancer*, *34 Suppl 2*, S53-58.
- Norton, R., Heuzenroeder, M., Manning, P.A. (1996). Non-specific serum binding to streptavidin in a biotinylated peptide based enzyme immunoassay. *J. immunoass*, *17*, 195-204.
- O'Driscoll, L., Linehan, R., & Clynes, M. (2003). Survivin: role in normal cells and in pathological conditions. *Curr Cancer Drug Targets*, *3*(2), 131-152.
- Oikarinen, A., Makela, J., Vuorio, T., & Vuorio, E. (1991). Comparison on collagen gene expression in the developing chick embryo tendon and heart. Tissue and development time-dependent action of dexamethasone. *Biochim Biophys Acta*, *1089*(1), 40-46.
- Okada, H., & Mak, T. W. (2004). Pathways of apoptotic and non-apoptotic death in tumour cells. *Nat Rev Cancer*, *4*(8), 592-603.
- Page, M., & Thorpe, R. (2002). Protein blotting by electroblotting. In J. Walker (Ed.), *The protein protocols handbook*. New Jersey: Humana Press.
- Partridge, M., Gaballah, K., & Huang, X. (2005). Molecular markers for diagnosis and prognosis. *Cancer Metastasis Rev*, *24*(1), 71-85.
- Pfeffer, U., Fecarotta, E., & Vidali, G. (1995). Efficient one-tube RT-PCR amplification of rare transcripts using short sequence-specific reverse transcription primers. *Biotechniques*, *18*(2), 204-206.

- Pizem, J., & Cor, A. (2003). Survivin - an inhibitor of apoptosis and a new therapeutic target in cancer. *Radiol Oncol*, 37(3), 195-201.
- Plantaz, D., Mohapatra, G., Matthay, K. K., Pellarin, M., Seeger, R. C., & Feuerstein, B. G. (1997). Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. *Am J Pathol*, 150(1), 81-89.
- Rao, G. N., Sardet, C., Pouyssegur, J., & Berk, B. C. (1990). Differential regulation of Na⁺/H⁺ antiporter gene expression in vascular smooth muscle cells by hypertrophic and hyperplastic stimuli. *J Biol Chem*, 265(32), 19393-19396.
- Reed, J. C. (2000). Mechanisms of apoptosis. *Am J Pathol*, 157(5), 1415-1430.
- Rohayem, J., Diestelkoetter, P., Weigle, B., Oehmichen, A., Schmitz, M., Mehlhorn, J., et al. (2000). Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. *Cancer Res*, 60(7), 1815-1817.
- Saitoh, Y., Yaginuma, Y., & Ishikawa, M. (1999). Analysis of Bcl-2, Bax and Survivin genes in uterine cancer. *Int J Oncol*, 15(1), 137-141.
- Sarela, A. I., Macadam, R. C., Farmery, S. M., Markham, A. F., & Guillou, P. J. (2000). Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. *Gut*, 46(5), 645-650.
- Satoh, K., Kaneko, K., Hirota, M., Masamune, A., Satoh, A., & Shimosegawa, T. (2001). Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. *Cancer*, 92(2), 271-278.

- Schatz, P. J. (1993). Use of peptide libraries to map the substrate specificity of a peptide-modifying enzyme: a 13 residue consensus peptide specifies biotinylation in *Escherichia coli*. *Biotechnology (N Y)*, *11*(10), 1138-1143.
- Schlette, E. J., Medeiros, L. J., Goy, A., Lai, R., & Rassidakis, G. Z. (2004). Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. *J Clin Oncol*, *22*(9), 1682-1688.
- Schmitt, C. A., Fridman, J. S., Yang, M., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002). Dissecting p53 tumor suppressor functions in vivo. *Cancer Cell*, *1*(3), 289-298.
- Skoufias, D. A., Mollinari, C., Lacroix, F. B., & Margolis, R. L. (2000). Human survivin is a kinetochore-associated passenger protein. *J Cell Biol*, *151*(7), 1575-1582.
- Smith, P. A., Tripp, B. C., DiBlasio-Smith, E. A., Lu, Z., LaVallie, E. R., & McCoy, J. M. (1998). A plasmid expression system for quantitative in vivo biotinylation of thioredoxin fusion proteins in *Escherichia coli*. *Nucleic Acids Res*, *26*(6), 1414-1420.
- Stonner-Liewen, F., & Reed, J. C. (2003). Apoptosis and Cancer: Basic Mechanisms and Therapeutic Opportunities in the Postgenomic Era. *Cancer Res*, *63*, 263-268.
- Stratech. (2006). Streptavidin and Conjugates [Online]. Available: http://www.stratech.co.uk/merchant.ihtml?new_id=1273&step=2 [2006, December 25].
- Swana, H. S., Grossman, D., Anthony, J. N., Weiss, R. M., & Altieri, D. C. (1999). Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. *N Engl J Med*, *341*(6), 452-453.

- Tamm, I., Wang, Y., Sausville, E., Scudiero, D. A., Vigna, N., Oltersdorf, T., et al. (1998). IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. *Cancer Res*, 58(23), 5315-5320.
- Tan, E. M. (2001). Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. *J Clin Invest*, 108(10), 1411-1415.
- Tanaka, K., Iwamoto, S., Gon, G., Nohara, T., Iwamoto, M., & Tanigawa, N. (2000). Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. *Clin Cancer Res*, 6(1), 127-134.
- Tokunaga, K., Nakamura, Y., Sakata, K., Fujimori, K., Ohkubo, M., Sawada, K., et al. (1987). Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. *Cancer Res*, 47(21), 5616-5619.
- Vatanasapt, V., Sriamporn, S., & Vatanasapt, P. (2002). Cancer control in Thailand. *Jpn J Clin Oncol*, 32 Suppl, S82-91.
- Velculescu, V. E., Madden, S. L., Zhang, L., Lash, A. E., Yu, J., Rago, C., et al. (1999). Analysis of human transcriptomes. *Nat Genet*, 23(4), 387-388.
- Verneris, M. R., Kornacker, M., Mailander, V., & Negrin, R. S. (2000). Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis. *Cancer Immunol Immunother*, 49(6), 335-345.
- Wang, L., Zhang, G. M., & Feng, Z. H. (2003). Down-regulation of survivin expression reversed multidrug resistance in adriamycin-resistant HL-60/ADR cell line. *Acta Pharmacol Sin*, 24(12), 1235-1240.

- Wheatley, S. P., Carvalho, A., Vagnarelli, P., & Earnshaw, W. C. (2001). INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosis. *Curr Biol*, *11*(11), 886-890.
- Williams, G. T., Critchlow, M. R., Hedge, V. L., & O'Hares, K. B. (1998). Molecular failure of apoptosis: inappropriate cell survival and mutagenesis? . *Toxicol Lett*, *102*, 485-489.
- Winkler, I. G., Lochelt, M., Levesque, J. P., Bodem, J., Flugel, R. M., & Flower, R. L. (1997). A rapid streptavidin-capture ELISA specific for the detection of antibodies to feline foamy virus. *J Immunol Methods*, *207*(1), 69-77.
- Wrzesien-Kus, A., Smolewski, P., Sobczak-Pluta, A., Wierzbowska, A., & Robak, T. (2004). The inhibitor of apoptosis protein family and its antagonists in acute leukemias. *Apoptosis*, *9*(6), 705-715.
- Yagihashi, A., Asanuma, K., Kobayashi, D., Tsuji, N., Shijubo, Y., Abe, S., et al. (2005). Detection of autoantibodies to livin and survivin in Sera from lung cancer patients. *Lung Cancer*, *48*(2), 217-221.
- Yagihashi, A., Asanuma, K., Kobayashi, D., Tsuji, N., Torigoe, T., Sato, N., et al. (2005). Autoantibodies to survivin in patients with chronic hepatitis and hepatocellular carcinoma. *Autoimmunity*, *38*(6), 445-448.
- Yagihashi, A., Asanuma, K., Nakamura, M., Araya, J., Mano, Y., Torigoe, T., et al. (2001). Detection of anti-survivin antibody in gastrointestinal cancer patients. *Clin Chem*, *47*(9), 1729-1731.
- Yagihashi, A., Ohmura, T., Asanuma, K., Kobayashi, D., Tsuji, N., Torigoe, T., et al. (2005). Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. *Clin Chim Acta*, *362*(1-2), 125-130.

- Yamamoto, T., & Tanigawa, N. (2001). The role of survivin as a new target of diagnosis and treatment in human cancer. *Med Electron Microsc*, 34(4), 207-212.
- Yoshida, H., Ishiko, O., Sumi, T., Matsumoto, Y., & Ogita, S. (2001). Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas. *Int J Oncol*, 19(3), 537-542.
- Zaffaroni, N., Pennati, M., & Daidone, M. G. (2005). Survivin as a target for new anticancer interventions. *J Cell Mol Med*, 9(2), 360-372.
- Zhang, J. Y. (2004). Tumor-associated antigen arrays to enhance antibody detection for cancer diagnosis. *Cancer Detect Prev*, 28(2), 114-118.
- Zhang, J. Y., Casiano, C. A., Peng, X. X., Koziol, J. A., Chan, E. K., & Tan, E. M. (2003). Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. *Cancer Epidemiol Biomarkers Prev*, 12(2), 136-143.
- Zhu, N., Gu, L., Findley, H. W., Li, F., & Zhou, M. (2004). An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. *Oncogene*, 23(45), 7545-7551.
- Zinkin, L. D. (1983). A critical review of the classifications and staging of colorectal cancer. *Dis Colon Rectum*, 26(1), 37-43.